These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 32554246

  • 1. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, Zhang H, Zi X, Zhou W, Huang G.
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [Abstract] [Full Text] [Related]

  • 2. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 3. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B.
    Aging (Albany NY); 2020 Nov 16; 12(22):22975-23003. PubMed ID: 33203790
    [Abstract] [Full Text] [Related]

  • 4. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M, Zhang L, Ge C, Chen L, Fang T, Li H, Tian H, Liu J, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J.
    Oncotarget; 2015 Sep 22; 6(28):25149-60. PubMed ID: 26327240
    [Abstract] [Full Text] [Related]

  • 5. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 6. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y, Huang Y, Dai T, Hua Z, Xu J, Lin Y, Han L, Yue X, Ho L, Lu J, Ai X.
    Biomed Pharmacother; 2021 Jan 06; 133():111030. PubMed ID: 33378944
    [Abstract] [Full Text] [Related]

  • 7. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
    Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ.
    PLoS One; 2013 Jan 06; 8(12):e83627. PubMed ID: 24391798
    [Abstract] [Full Text] [Related]

  • 8. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
    Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang G, Liu Y, Yao Y, Chen X, Ma W, Zhang Z, Yuan Y.
    Cell Death Dis; 2021 Jul 09; 12(7):691. PubMed ID: 34244479
    [Abstract] [Full Text] [Related]

  • 9. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
    Hou H, Sun H, Lu P, Ge C, Zhang L, Li H, Zhao F, Tian H, Zhang L, Chen T, Yao M, Li J.
    Mol Cancer Ther; 2013 Dec 09; 12(12):2874-84. PubMed ID: 24130050
    [Abstract] [Full Text] [Related]

  • 10. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H, Xu H, Ma F, Zhan M, Yang X, Hua S, Li W, Li Y, Lu L.
    Cell Death Dis; 2020 Apr 08; 11(4):225. PubMed ID: 32269215
    [Abstract] [Full Text] [Related]

  • 11. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 08; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 12. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J.
    Theranostics; 2021 Jun 08; 11(12):6006-6018. PubMed ID: 33897895
    [Abstract] [Full Text] [Related]

  • 13. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
    Wang P, Jiang Z, Liu X, Yu K, Wang C, Li H, Zhong L.
    Cancer Med; 2020 Oct 08; 9(19):6972-6983. PubMed ID: 32779397
    [Abstract] [Full Text] [Related]

  • 14. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.
    Zhang X, Wang W, Mo S, Sun X.
    Dig Dis Sci; 2024 Jun 08; 69(6):2096-2108. PubMed ID: 38653946
    [Abstract] [Full Text] [Related]

  • 15. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway.
    Li B, Liu D, Yang P, Li HY, Wang D.
    Gene; 2019 Jul 30; 707():78-85. PubMed ID: 31075412
    [Abstract] [Full Text] [Related]

  • 16. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
    Zhang Z, He CZ, Qin YQ, Liao JJ, Huang ST, Mo S, Li HM, Lin JY.
    Aging (Albany NY); 2020 Nov 21; 12(23):24255-24269. PubMed ID: 33234725
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL, Cheng CL, Li MY, Yang SL, Hu BG, Chong CCN, Chan SL, Ren J, Chen GG, Lai PBS.
    Cell Death Dis; 2018 Aug 28; 9(9):852. PubMed ID: 30154433
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment.
    Chen B, Pan Y, Xu X, Wu F, Zheng X, Chen SY, Zhao YT, Huang Z, Cheng SH, Liu JX, Wang WH, Li YX.
    Biomed Pharmacother; 2020 Aug 28; 128():110284. PubMed ID: 32480224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.